Virtus ETF Advisers’s Rubius Therapeutics, Inc RUBY Stock Holding History

Virtus ETF Advisers’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,052	Closed	-$66K	–	494
2022 Q1	$66K	Sell	12,052 -721	-6%	-$4.58K	0.03%	356
2021 Q4	$124K	Buy	12,773 +5,295	+71%	+$73.4K	0.05%	369
2021 Q3	$134K	Sell	7,478 -390	-5%	-$8.48K	0.06%	361
2021 Q2	$192K	Sell	7,868 -26,528	-77%	-$664K	0.08%	369
2021 Q1	$911K	Buy	34,396 +603	+2%	+$8.81K	0.38%	96
2020 Q4	$256K	Sell	33,793 -17,070	-34%	-$101K	0.11%	305
2020 Q3	$255K	Sell	50,863 -6,930	-12%	-$36.7K	0.13%	258
2020 Q2	$346K	Buy	+57,793	New	+$341K	0.16%	268

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtus ETF Advisers's RUBY Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 12,052 shares — an estimated $66K sold.

Virtus ETF Advisers first reported a position in RUBY in Q2 2020 and held it in 8 quarters. The position peaked at $911K in Q1 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

Virtus ETF Advisers reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
Virtus ETF Advisers sold 12,052 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $66K.
Virtus ETF Advisers first reported a position in Rubius Therapeutics, Inc in Q2 2020 and held it in 8 quarters.
Virtus ETF Advisers's Rubius Therapeutics, Inc position peaked at $911K in Q1 2021.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.